May 18th, 2023

HemoShear Therapeutics Participates in Piper Sandler Symposium

Read More »
May 4th, 2023

Shear Insights: From Crisis to Opportunity: HemoShear Continues to Obtain Tissue to Advance Research

Read More »
March 15th, 2023

Shear Insights: HemoShear Therapeutics Attends Family and Scientific Meetings

Read More »
February 10th, 2023

Shear Insights: Medical Journal Publishes HemoShear Pilot

Read More »
December 9th, 2022

Shear Insights: Parents Share Their Children’s Journey with Methylmalonic Acidemia

Read More »
November 17th, 2022

HemoShear Therapeutics to Participate in Piper Sandler Healthcare Conference

Read More »
October 18th, 2022

HemoShear Therapeutics to Participate in SVB Leerink Securities Biopharma Private Company Connect

Read More »
October 11th, 2022

Shear Insights: HemoShear Therapeutics Has Built a World Class Drug Discovery Organization to Advance its Rare Disease Portfolio

Read More »
September 21st, 2022

HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline

Read More »
August 25th, 2022

HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer

Read More »
August 10th, 2022

HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda

Read More »

The JUMP Study Poster

Read More »
View More +


HemoShear Therapeutics, Inc.
501 Locust Avenue
Suite 301
Charlottesville, Virginia 22902